By Jimmy Hoover ( July 5, 2016, 6:40 PM EDT) -- GlaxoSmithKline pressed a Federal Circuit panel Tuesday to revive an application for an inhalation treatment for the influenza virus that was rejected by the Patent Trial and Appeals Board, arguing all prior flu treatments with the same compound were nasal sprays....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.